Relmada Therapeutics pivots to NDV-01 for bladder cancer & Sepranolone for Tourette's. Phase 2 results expected April 2025.

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCCUpdated data from ongoing Phase 1/1b trial in 1L ...

Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in Parkinson’s ...

Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to ...

The curated sections at art fairs are often a focal point for collectors and curators­—this looks to be the case with Art ...

A typical zongo boy hardly takes a courageous move of responding to a “Call for Abstract and academic paper presentation” at ...

Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Vibrant portraits, layered sculptures, and imaginative murals filled the Galleries at LynnArts this week as hundreds of Lynn ...